Desenvolvimento de resistência antimicrobiana devido ao Coronavírus da Síndrome Respiratória Aguda Grave 2 (SARS-CoV-2)
DOI:
https://doi.org/10.33448/rsd-v10i16.24207Palavras-chave:
Coronavírus da Síndrome Respiratória Aguda Grave 2; COVID-19; Pandemia; Saúde pública; Antibióticos; Bactéria; Resistência antimicrobiana; Infecções bacterianas.Resumo
Coronavírus da Síndrome Respiratória Aguda Grave 2 (SARS-CoV-2) é um novo coronavírus identificado em 2019. Esta doença, que pode causar uma infecção respiratória grave, foi designada uma emergência internacional de saúde pública e está sendo tratada com vários tipos de antivirais, antibióticos e antifúngicos. Embora o mundo trabalhe para combater e controlar a pandemia da doença do coronavírus 2019 (COVID-19), é igualmente importante estarmos preparados para os efeitos devastadores desse surto no desenvolvimento da resistência antimicrobiana (AMR). Durante a atual pandemia, espera-se que o uso incorreto e excessivo de antibióticos tenha consequências graves nos programas de administração de antibióticos e gerenciamento de AMR em todo o mundo. É importante ressaltar que a influência global na criação de uma nova resistência antimicrobiana é incerta devido à escassez de dados sobre o uso de antimicrobianos durante a pandemia causada pelo SARS-CoV-2. No futuro, a atual pandemia pode ser uma ferramenta útil para descrever a propagação da resistência antimicrobiana e destacar as dificuldades em gerenciar o problema, uma vez que o mesmo tenha surgido. Esta revisão tem como objetivo avaliar os dados disponíveis sobre infecções bacterianas em pacientes infectados pelo novo coronavírus e oferecer uma visão sobre o que esperar da resistência antimicrobiana e do desenvolvimento de antimicrobianos em face do atual problema de saúde pública.
Referências
Bai, L., Du, P., Du, Y., Sun, H., Zhang, P., Wan, Y., Lin, Q., Fanning, S., Cui, S., & Wu, Y. (2019). Detection of plasmid-mediated tigecycline-resistant gene tet(X4) in Escherichia coli from pork, sichuan and shandong provinces, China, february 2019. Eurosurveillance, 24(25), 7–10. https://doi.org/10.2807/1560-7917.ES.2019.24.25.1900340
Ban on antibiotics as growth promoters in animal feed enters into effect. (2005). Brussels: European Commission.
Barker, K. (2020). Lawmakers, experts warn of U.S. reliance on foreign-made drugs, medical products. https://www.joplinglobe.com/news/local_news/lawmakers-experts-warn-of-u-s-reliance-on-foreign-made/article_cc1332e0-e7e7-5cba-9089-f9ec5bf8a3f6.html
Baron, S. A., Devaux, C., Colson, P., Raoult, D., & Rolain, J. M. (2020). Teicoplanin: An alternative drug for the treatment of COVID-19? International Journal of Antimicrobial Agents, 55(4), 105944. https://doi.org/10.1016/j.ijantimicag.2020.105944
Baur, D., Gladstone, B., Burket, F., Carrara, E., Foschi, F., Dobele, S., & Tacconelli, E. (2017). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: A systematic review and meta-analysis. The Lancet Infectious Diseases, 17(9), 990–1001. https://doi.org/10.1016/S1473-3099(17)30325-0
Bhatraju, P. K., Ghassemieh, B. J., Nichols, M., Kim, R., Jerome, K. R., Nalla, A. K., Greninger, A. L., Pipavath, S., Wurfel, M. M., Evans, L., Kritek, P. A., West, T. E., Luks, A., Gerbino, A., Dale, C. R., Goldman, J. D., O’Mahony, S., & Mikacenic, C. (2020). Covid-19 in critically ill patients in the Seattle region — Case series. New England Journal of Medicine, 382(21), 2012–2022. https://doi.org/10.1056/nejmoa2004500
Bhatt, T., Kumar, V., Pande, S., Malik, R., Khamparia, A., & Gupta, D. (2021). A review on COVID-19. Studies in Computational Intelligence, 924(April), 25–42. https://doi.org/10.1007/978-3-030-60188-1_2
Borek, A. J., Wanat, M., Sallis, A., Ashiru-Oredope, D., Atkins, L., Beech, E., Hopkins, S., Jones, L., McNulty, C., Shaw, K., Taborn, E., Butler, C., Chadborn, T., & Tonkin-Crine, S. (2019). How can national antimicrobial stewardship interventions in primary care be improved? A stakeholder consultation. Antibiotics, 8(4). https://doi.org/10.3390/antibiotics8040207
Cantón, R., & Coque, T. M. (2006). The CTX-M β-lactamase pandemic. Current Opinion in Microbiology, 9(5), 466–475. https://doi.org/10.1016/j.mib.2006.08.011
Cao, J., Tu, W., Cheng, W., & Yu, L. (2019). Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan , China. Oxford University Press, 238, 4–21.
Castanheira, M., Griffin, M. A., Deshpande, L. M., Mendes, R. E., Jones, R. N., & Flamm, R. K. (2016). Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. Antimicrobial Agents and Chemotherapy, 60(9), 5623–5624. https://doi.org/10.1128/AAC.01267-16
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, 130(5), 2620–2629. https://doi.org/10.1172/JCI137244
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., Wang, T., Guo, W., Chen, J., Ding, C., Zhang, X., Huang, J., Han, M., Li, S., Luo, X., … Ning, Q. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ, 368. https://doi.org/10.1136/bmj.m1091
Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., Yang, B., Ding, J., & Li, F. (2020). Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clinical Infectious Diseases, 17. https://doi.org/10.1093/cid/ciaa449
Chen, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. The Lancet. https://doi.org/10.1016/S0140-6736(20)30211-7
Clancy, C. J., & Nguyen, M. (2020). Coronavirus disease 2019, superinfections, and antimicrobial development: What can we expect? Clinical Infectious Diseases, 71(10), 2736–2743. https://doi.org/10.1093/cid/ciaa524
Cong, W., Poudel, A. N., Aihusein, N., Wang, H., Yao, G., & Lambert, H. (2021). Antimicrobial use in covid-19 patients in the first phase of the sars-cov-2 pandemic: A scoping review. Antibiotics, 10(6), 1–14. https://doi.org/10.3390/antibiotics10060745
Dong, X., Cao, Y. yuan, Lu, X. xia, Zhang, J. jin, Du, H., Yan, Y. qin, Akdis, C. A., & Gao, Y. dong. (2020). Eleven faces of coronavirus disease 2019. Allergy: European Journal of Allergy and Clinical Immunology, 75(7), 1699–1709. https://doi.org/10.1111/all.14289
Du, Y., Tu, L., Zhu, P., Mu, M., Wang, R., Yang, P., Wang, X., Hu, C., Ping, R., Hu, P., Li, T., Cao, F., Chang, C., Hu, Q., Jin, Y., & Xu, G. (2020). Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. American Journal of Respiratory and Critical Care Medicine, 201(11), 1372–1379. https://doi.org/10.1164/rccm.202003-0543OC
Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., Penzar, D., Perlman, S., Poon, L. L. M., Samborskiy, D. V., Sidorov, I. A., Sola, I., & Ziebuhr, J. (2020). The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology, 5(4), 536–544. https://doi.org/10.1038/s41564-020-0695-z
Goyal, P., Choi, J., & Pinheiro, L. (2020). Clinical characteristics of Covid-19 in New York City. New England Journal of Medicine, 382(24), 2372–2374. https://doi.org/10.1056/NEJMc2010419
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., Iotti, G., Latronico, N., Lorini, L., Merler, S., Natalini, G., Piatti, A., Ranieri, M. V., Scandroglio, A. M., Storti, E., … Pesenti, A. (2020). Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA - Journal of the American Medical Association, 323(16), 1574–1581. https://doi.org/10.1001/jama.2020.5394
Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K.-Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., … Zhong, N. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine, 382(18), 1708–1720. https://doi.org/10.1056/nejmoa2002032
Guidance on COVID-19: Interim guidance for primary care. (2020). HRM Government. https://www.gov.uk/government/ publications/wn- cov- guidance- for- primary- care/wn- cov- interim- guidance- for-primary-care
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(January), 497–506.
IAGG. (2019). No time to wait: securing the future from drug-resistant infections. https://www.who.int/antimicrobial-resistance/interagency-%0Acoordination- group/final- report/en
Kahn, L. H. (2017). Antimicrobial resistance: A one health perspective. Transactions of the Royal Society of Tropical Medicine and Hygiene, 111(6), 255–260. https://doi.org/10.1093/trstmh/trx050
Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., & Hsueh, P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents, 55(3), 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
Langford, B. J., So, M., Raybardhan, S., Leung, V., Westwood, D., MacFadden, D. R., Soucy, J. P. R., & Daneman, N. (2020). Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clinical Microbiology and Infection, 26(12), 1622–1629. https://doi.org/10.1016/j.cmi.2020.07.016
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J. A., Klugman, K., & Davies, S. (2016). Access to effective antimicrobials: A worldwide challenge. The Lancet, 387(10014), 168–175. https://doi.org/10.1016/S0140-6736(15)00474-2
Lian, J., Jin, X., Hao, S., Cai, H., Zhang, S., Zheng, L., Jia, H., Hu, J., Gao, J., Zhang, Y., Zhang, X., Yu, G., Wang, X., Gu, J., Ye, C., Jin, C., Lu, Y., Yu, X., Yu, X., … Yang, Y. (2020). Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan. Clinical Infectious Diseases, 71(15), 740–747. https://doi.org/10.1093/cid/ciaa242
Liang, Z., Li, L., Wang, Y., Chen, L., Kong, X., Hong, Y., Lan, L., Zheng, M., Guang-Yang, C., Liu, H., Shen, X., Luo, C., Li, K. K., Chen, K., & Jiang, H. (2011). Molecular basis of NDM-1, a new antibiotic resistance determinant. PLoS ONE, 6(8), 4–11. https://doi.org/10.1371/journal.pone.0023606
Liu, Y., Wang, Y., Walsh, T., Yi, L., Zhang, R., Spencer, J., Doi, Y., Tian, G., Dong, B., Huang, X., Yu, L., & Gu, D. (2016). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. The Lancet Infectious Disease, 16(2), 161–168. https://doi.org/10.1016/S1473-3099(15)00424-7
Manohar, P., Loh, B., & Leptihn, S. (2020). Will the overuse of antibiotics during the coronavirus pandemic accelerate antimicrobial resistance of bacteria? Infectious Microbes and Diseases, 2(3), 87–88. https://doi.org/10.1097/im9.0000000000000034
Murray, A. K. (2020). The novel coronavirus COVID-19 outbreak: Global implications for antimicrobial resistance. Frontiers in Microbiology, 11(May), 1–4. https://doi.org/10.3389/fmicb.2020.01020
Nordmann, P., Poirel, L., Walsh, T., & Livermore, D. (2011). The emerging NDM carbapenemases. Trends in Microbiology, 19(12). https://doi.org/10.1016/j.tim.2011.09.005
O’Neil, J. (2016). Trackling drug-resistant infections globally: final report and recommendations.
ÖstholmBalkhed, Å., Tärnberg, M., Nilsson, M., Nilsson, L. E., Hanberger, H., & Hällgren, A. (2018). Duration of travel-associated faecal colonisation with ESBL-producing enterobacteriaceae - A one year follow-up study. PLoS ONE, 13(10), 1–12. https://doi.org/10.1371/journal.pone.0205504
Pedersen, S. F., & Ho, Y. C. (2020). SARS-CoV-2: A storm is raging. Journal of Clinical Investigation, 130(5), 2202–2205. https://doi.org/10.1172/JCI137647
Rawson, T. M., Moore, L. S. P., Castro-Sanchez, E., Charani, E., Davies, F., Satta, G., Ellington, M. J., & Holmes, A. H. (2020). COVID-19 and the potential long-term impact on antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 75(7), 1681–1684. https://doi.org/10.1093/jac/dkaa194
Rawson, T. M., Moore, L. S. P., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., Satta, G., Cooke, G., & Holmes, A. (2020). Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clinical Infectious Diseases, 71(9), 2459–2468. https://doi.org/10.1093/cid/ciaa530
Ruan, Z., & Feng, Y. (2016). BacWGSTdb, a database for genotyping and source tracking bacterial pathogens. Nucleic Acids Research, 44(D1), D682–D687. https://doi.org/10.1093/nar/gkv1004
Walsh, T., & Wu, Y. (2016). China bans colistin as a feed additive for animals. The Lancet Infectious Disease, 16(10). https://doi.org/10.1016/S1473-3099(16)30329-2
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA - Journal of the American Medical Association, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585
Wang, Z., Yang, B., Li, Q., Wen, L., & Zhang, R. (2020). Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clinical Infectious Diseases, 71(15), 769–777. https://doi.org/10.1093/cid/ciaa272
White, A., & Hughes, J. M. (2019). Critical importance of a One Health approach to antimicrobial resistance. EcoHealth, 16(3), 404–409. https://doi.org/10.1007/s10393-019-01415-5
WHO. (2020a). Clinical management of severe acute respiratory infection when COVID-19 is suspected. https://www.who.int/publications-detail/clinic al-management-of-severe-acute-respiratory-infection-when-novel-corona virus-(ncov)-infection-is-suspected
WHO. (2020b). WHO campaigns: World Antibiotic Awareness Week.
WHO. (2021). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Xu, X. W., Wu, X. X., Jiang, X. G., Xu, K. J., Ying, L. J., Ma, C. L., Li, S. B., Wang, H. Y., Zhang, S., Gao, H. N., Sheng, J. F., Cai, H. L., Qiu, Y. Q., & Li, L. J. (2020). Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. The BMJ, 368(January), 1–7. https://doi.org/10.1136/bmj.m606
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., & Shang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med., 8(5), 475–481. https://doi.org/10.1016/S2213-2600(20)30079-5
Zhou, F. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Journal of Medicine Study & Research, 3(1), 01–02. https://doi.org/10.24966/msr-5657/100015
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2021 Débora Brito Goulart
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
